FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923871137> ?p ?o ?g. }

• W2923871137 abstract "Background: EGFR TKIs have shown first-line efficacy in EGFR m+ NSCLC but acquired resistance is inevitable; with afatinib, this is predominantly through the emergence of T790M. Therefore, a key consideration when assessing therapeutic choices is the availability of subsequent treatment options. The GioTag study (NCT03370770) is the first to assess outcomes of real-world patients (Pts) who received first-line afatinib followed by osimertinib; for pts with EGFR m+ NSCLC and acquired T790M this sequence resulted in a median time on treatment (ToT) of 27.6 months, which did not include chemotherapy. We present subgroup analyses of pts from the GioTag study who are under-represented in randomized controlled trials (RCTs) and assess the impact of afatinib treatment on ECOG PS. Methods: The GioTag study is an observational, multicenter study. Data were collected retrospectively (Dec 2017–May 2018). Pts had EGFR m+ (Del19/L858R) advanced NSCLC and acquired T790M after first-line afatinib. Pts completed afatinib and started osimertinib treatment ≥10 months before data entry to avoid early censoring and ensure mature data collection. Patient subgroups were defined based on baseline characteristics (eg, ECOG PS, age, ethnicity). The primary outcome was ToT from afatinib initiation to osimertinib discontinuation. Results: A total of 204 pts were included in the GioTag study: 15.2% had ECOG PS ≥2; 7.4% were aged ≥75 years; 8.8% were African-American. Pts generally considered to have a poor prognosis derived clinical benefit from the afatinib–osimertinib sequence: median ToT for pts with ECOG PS ≥2 (n=31) was 22.2 months (90%CI 16.0–27.0; vs pts with ECOG PS 0/1 [n=153; 31.3 months; 27.6–44.5] P <.001); and for pts aged ≥75 years (n=15), ToT was 19.9 months (9.7–not evaluable [NE]; vs pts aged <75 years [n=189; 28.1 months; 26.6–31.3] P =.382). In African-American pts, median ToT was 27.6 months (90%CI 24.7–NE). Of 180 pts with available data, 75.0% had no change or an improvement in ECOG PS from the start of afatinib to the start of osimertinib treatment; 24.4% of pts had a deterioration in ECOG PS by 1 step and 0.6% of pts had a deterioration by 2 steps. Conclusions: First-line afatinib followed by osimertinib is a feasible therapeutic strategy in pts with EGFR m+ NSCLC and acquired T790M, including those who are often under-represented in RCTs. Clinical benefit (measured by ToT) was seen among pts with poor prognosis (ECOG PS ≥2), pts aged ≥75 years, and African-American pts." @default.
• W2923871137 created "2019-04-01" @default.
• W2923871137 creator A5010679703 @default.
• W2923871137 creator A5012226414 @default.
• W2923871137 creator A5022345552 @default.
• W2923871137 creator A5032293215 @default.
• W2923871137 creator A5045531429 @default.
• W2923871137 creator A5051933262 @default.
• W2923871137 creator A5059278629 @default.
• W2923871137 creator A5059795069 @default.
• W2923871137 creator A5068475432 @default.
• W2923871137 creator A5075625203 @default.
• W2923871137 creator A5081356537 @default.
• W2923871137 date "2019-03-08" @default.
• W2923871137 modified "2023-09-28" @default.
• W2923871137 title "CLO19-033: Afatinib Followed by Osimertinib in EGFR Mutation-Positive (EGFRm+) Advanced NSCLC: Subgroup Analyses of the GioTag Study by ECOG PS, Age, and Ethnicity" @default.
• W2923871137 doi "https://doi.org/10.6004/jnccn.2018.7184" @default.
• W2923871137 hasPublicationYear "2019" @default.
• W2923871137 type Work @default.
• W2923871137 sameAs 2923871137 @default.
• W2923871137 citedByCount "0" @default.
• W2923871137 crossrefType "journal-article" @default.
• W2923871137 hasAuthorship W2923871137A5010679703 @default.
• W2923871137 hasAuthorship W2923871137A5012226414 @default.
• W2923871137 hasAuthorship W2923871137A5022345552 @default.
• W2923871137 hasAuthorship W2923871137A5032293215 @default.
• W2923871137 hasAuthorship W2923871137A5045531429 @default.
• W2923871137 hasAuthorship W2923871137A5051933262 @default.
• W2923871137 hasAuthorship W2923871137A5059278629 @default.
• W2923871137 hasAuthorship W2923871137A5059795069 @default.
• W2923871137 hasAuthorship W2923871137A5068475432 @default.
• W2923871137 hasAuthorship W2923871137A5075625203 @default.
• W2923871137 hasAuthorship W2923871137A5081356537 @default.
• W2923871137 hasConcept C121608353 @default.
• W2923871137 hasConcept C126322002 @default.
• W2923871137 hasConcept C137403100 @default.
• W2923871137 hasConcept C143998085 @default.
• W2923871137 hasConcept C144024400 @default.
• W2923871137 hasConcept C19165224 @default.
• W2923871137 hasConcept C2775999482 @default.
• W2923871137 hasConcept C2777626846 @default.
• W2923871137 hasConcept C2779438470 @default.
• W2923871137 hasConcept C2780580887 @default.
• W2923871137 hasConcept C2780586478 @default.
• W2923871137 hasConcept C2781182431 @default.
• W2923871137 hasConcept C71924100 @default.
• W2923871137 hasConceptScore W2923871137C121608353 @default.
• W2923871137 hasConceptScore W2923871137C126322002 @default.
• W2923871137 hasConceptScore W2923871137C137403100 @default.
• W2923871137 hasConceptScore W2923871137C143998085 @default.
• W2923871137 hasConceptScore W2923871137C144024400 @default.
• W2923871137 hasConceptScore W2923871137C19165224 @default.
• W2923871137 hasConceptScore W2923871137C2775999482 @default.
• W2923871137 hasConceptScore W2923871137C2777626846 @default.
• W2923871137 hasConceptScore W2923871137C2779438470 @default.
• W2923871137 hasConceptScore W2923871137C2780580887 @default.
• W2923871137 hasConceptScore W2923871137C2780586478 @default.
• W2923871137 hasConceptScore W2923871137C2781182431 @default.
• W2923871137 hasConceptScore W2923871137C71924100 @default.
• W2923871137 hasLocation W29238711371 @default.
• W2923871137 hasOpenAccess W2923871137 @default.
• W2923871137 hasPrimaryLocation W29238711371 @default.
• W2923871137 isParatext "false" @default.
• W2923871137 isRetracted "false" @default.
• W2923871137 magId "2923871137" @default.
• W2923871137 workType "article" @default.